X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DIVIS LABORATORIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DIVIS LABORATORIES PANACEA BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x -6.7 34.4 - View Chart
P/BV x 2.0 6.7 30.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DIVIS LABORATORIES
Mar-18
PANACEA BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1491,142 13.0%   
Low Rs82533 15.4%   
Sales per share (Unadj.) Rs84.1146.6 57.4%  
Earnings per share (Unadj.) Rs-18.333.0 -55.4%  
Cash flow per share (Unadj.) Rs-6.738.4 -17.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs83.7222.8 37.6%  
Shares outstanding (eoy) m61.25265.47 23.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.45.7 24.0%   
Avg P/E ratio x-6.325.3 -24.9%  
P/CF ratio (eoy) x-17.221.8 -79.1%  
Price / Book Value ratio x1.43.8 36.7%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m7,074222,318 3.2%   
No. of employees `0002.810.8 25.6%   
Total wages/salary Rs m1,4494,561 31.8%   
Avg. sales/employee Rs Th1,874.13,616.0 51.8%   
Avg. wages/employee Rs Th527.0423.8 124.4%   
Avg. net profit/employee Rs Th-407.7814.9 -50.0%   
INCOME DATA
Net Sales Rs m5,15438,915 13.2%  
Other income Rs m1001,134 8.8%   
Total revenues Rs m5,25440,049 13.1%   
Gross profit Rs m-76612,617 -6.1%  
Depreciation Rs m7111,425 49.9%   
Interest Rs m1,50313 11,300.8%   
Profit before tax Rs m-2,88112,313 -23.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m173,543 0.5%   
Profit after tax Rs m-1,1218,770 -12.8%  
Gross profit margin %-14.932.4 -45.9%  
Effective tax rate %-0.628.8 -2.0%   
Net profit margin %-21.822.5 -96.5%  
BALANCE SHEET DATA
Current assets Rs m3,81045,351 8.4%   
Current liabilities Rs m8,3656,507 128.6%   
Net working cap to sales %-88.499.8 -88.5%  
Current ratio x0.57.0 6.5%  
Inventory Days Days156127 122.9%  
Debtors Days Days6795 70.7%  
Net fixed assets Rs m14,48021,160 68.4%   
Share capital Rs m61531 11.5%   
"Free" reserves Rs m90358,625 1.5%   
Net worth Rs m5,12759,156 8.7%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43367,832 28.6%  
Interest coverage x-0.9926.8 -0.1%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.6 46.2%   
Return on assets %2.012.9 15.2%  
Return on equity %-21.914.8 -147.5%  
Return on capital %3.620.8 17.5%  
Exports to sales %24.50-   
Imports to sales %10.221.8 46.7%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m5258,485 6.2%   
Fx inflow Rs m1,53932,359 4.8%   
Fx outflow Rs m9429,042 10.4%   
Net fx Rs m59723,317 2.6%   
CASH FLOW
From Operations Rs m5997,759 7.7%  
From Investments Rs m-438-4,783 9.2%  
From Financial Activity Rs m-303-3,142 9.6%  
Net Cashflow Rs m-141-166 85.1%  

Share Holding

Indian Promoters % 74.5 52.0 143.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.8 5.1%  
FIIs % 1.3 19.0 6.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.2 137.2%  
Shareholders   10,259 31,796 32.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Dec 7, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - DR. DATSONS LABS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS